Psoriasis

The FDA assigned a Prescription Drug User Fee Act action date of May 22, 2025.

The study authors recommend that health care professionals are aware of the connections, notably in adolescent patients and those with moderate to severe psoriasis.

Ustekinumab-ttwe (Pyzchiva; Sandoz) is approved for all of the same indications as Stelara.

These options are typically more cost-effective, enhancing patient accessibility

Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody that treats immune-mediated diseases such as psoriasis and psoriatic arthritis.

To date, this is the only targeted therapy indicated for the treatment of generalized pustular psoriasis.

Compared to placebo, risankizumab significantly reduced symptom severity for patients with moderate to severe disease.

The tool consolidates and highlights key features that would be considered when choosing a biosimilar adalimumab.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

Adalimumab-ryvk is the first high-concentration, citrate-free biosimilar to Humira that has been granted interchangeability status for the 40 mg/0.4 ml injection.

Biologics for plaque psoriasis has been associated with an atopic dermatitis phenotype, paradoxical eczema, but the risk factors are not well known.

The biosimilar, now legally available at the pharmacy level, demonstrated similar safety, purity, and potency to the reference product.

Bimekizumab is a novel, humanized monoclonal IgG1 antibody that potently and selectively neutralizes both IL-7A and IL-17F, which are key cytokines driving inflammatory processes in plaque psoriasis.

The intravenous formulation of secukinumab is administered in monthly 30-minute, weight-based dosing and requires no pre-medication or lab monitoring.

Roflumilast is the first topical agent indicated to treat psoriasis in sensitive intertriginous areas of the skin.

Patients on risankizumab also reported greater satisfaction with treatment for moderate plaque psoriasis.

FDA approvals of these biosimilars started in 2016, but only 1 such product has successfully launched.

As more becomes known about Crohn disease, treatment modalities have evolved with biologic monoclonal antibodies becoming a key part of guideline- and evidence-based medicine.

Adalimumab-adbm (Cyltezo Pen; Boehringer Ingelheim) is approved by the FDA as an interchangeable biosimilar to Humira.

Deuvacracitinib (Sotyktu), which the FDA approved in September 2022, is a first-of-its-class tyrosine kinase 2 inhibitor and a member of the Janus kinase family.

Due to the disease’s chronicity, the variability in treatment response and drug safety profiles, and the availability of multiple therapies, switching or discontinuing treatments is common in psoriasis.

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

The drug is indicated for moderate to severe plaque psoriasis.

Several studies have noted a potential link between methotrexate and an increased risk of skin cancer.

Results from the phase 2 and long-term trials will be presented later this year, following further data collection.

Air pollution from the California Camp Fire are associated with increased rates of clinical; visits, according to new study results.

Deucravacitinib is an oral, selective, allosteric tyrosine kinase 2 inhibitor that inhibits cytokine signaling in psoriasis pathogenesis.

The findings provide an alternative delivery strategy for peptide-based drugs and suggest that such techniques and principles could be applied to a broader range of drugs.